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Abstract. The apolipoprotein E (APOE) ε4 allele is a risk factor for the neuropathological decline accompanying Alzheimer’s
disease (AD) while, conversely, the ε2 allele offers protection. One of the brain structures exhibiting the earliest changes
associated with the disease is the entorhinal cortex. We therefore investigated the volumes of the entorhinal cortex and other
structures in the medial temporal lobe including the parahippocampal gyrus, temporal pole, and inferior, middle, and superior
temporal cortices, in relation to APOE genotype. Our main objectives were to determine if (a) volumes systematically varied
according to allele in a stepwise fashion, ε2 > ε3 > ε4, and (b) associations varied according to age. We investigate this association
in 627 non-demented community-dwelling adults in middle age (44 to 48 years; n= 314) and older age (64 to 68 years; n= 313)
who underwent structural MRI scans. We found no evidence of APOE-related variation in brain volumes in the age groups
examined. We conclude that if a ε2 > ε3 > ε4 pattern in brain volumes does emerge in non-demented adults living in the
community in old age, it is not until after the age of 68 years.
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Recent work [1] in children, adolescents, and young
adults up to age 21 years has shown that the entorhinal
cortex thickness varies according to apolipoprotein E
(APOE) genotype in a stepwise pattern; ε2 carriers’
entorhinal cortex thickness exceeds ε3 carriers who, in
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turn, exceed ε4 carriers. It is well established that in
later life, possession of the ε4 allele is associated with
cognitive deficits [2, 3], cerebral atrophy, and func-
tional changes [4], and is a risk factor for Alzheimer’s
disease (AD) (e.g., [5]). By contrast, the ε2 allele may
confer protection against age-related neuropathology
in old age (e.g., [6]).
If the APOE-related variation in entorhinal cor-
tex thickness found in young persons extends
into middle and late adulthood, it may provide a
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neurobiological mechanism that mediates vulnerabil-
ity to cognitive impairment and AD. That is, the greater
the entorhinal cortex thickness, the greater the protec-
tion offered. This possibility is of some importance as
there is evidence that the entorhinal cortex is one of
the first areas of the brain to exhibit and be severely
affected by the neuropathology associated with AD
[7–9]. Indeed, such neuropathological changes have
been detected in young adulthood and middle age
[10, 11]. It is possible that in ε2 carriers, the critical
threshold through which an individual must pass before
neurological impairment is manifest may be higher due
to the greater cortical thickness. Conversely, in ε4 car-
riers, that threshold may be lower due to the reduced
entorhinal cortex thickness [1].
Studies that have looked specifically at the entorhi-
nal cortex as a function of APOE genotype in
cognitively intact adults are relatively consistent in
their findings. For example, a study [12] of 25 persons
with a family history of AD and 25 persons without
this risk factor (overall mean age = 62.3 years) found
that a family history of AD and possession of the ε4
allele was associated additively with thinner entorhinal
cortex thickness. Although not taking family history
into account, similar results were obtained in another
investigation of 14 ε4 carriers and 16 non-carriers
(overall mean age = 57 years); ε4 carriers exhibited
thinner entorhinal cortex thickness than non-carriers
[13]. Against this work showing ε4 carriers to have
reduced entorhinal cortex sizes, longitudinal research
produces mixed results. For example, work investigat-
ing the entorhinal cortex and hippocampal atrophy over
an approximate 3.5-year period in 42 persons aged 58
to 87 years found no evidence that the rate of atrophy
varied according to APOE genotype [14]. By con-
trast, another study over a two year period [15] found
significantly greater entorhinal cortex thinning in 16
cognitively intact ε4 carriers relative to 16 non-carriers,
mean age 61 years.
On balance, much of the work in cognitively intact
adults suggests that the entorhinal cortex volume or
thickness is reduced in ε4 carriers relative to non-
carriers. However, several features of this work are
of note. First, all of the studies have relatively small
sample sizes. Second, they all compare ε4 carriers to
non-carriers and none have contrasted entorhinal cor-
tex volumes or thickness for ε2 versus ε3 versus ε4
genotypes. Finally, the studies have either investigated
restricted age ranges in older adults, or where a wider
age range has been employed, the sample size is not
sufficiently large to allow for a robust test of age effects
on APOE-entorhinal cortex associations.
While research has shown the entorhinal cortex
thickness to vary according to APOE genotype (i.e.,
ε2 > ε3 > ε4) in children, adolescents, and young adults
[1], no work has systematically explored whether this
association extends into middle age, and becomes more
marked in older age in a large-scale population-based
sample. As this may provide important information
on later life vulnerability to cognitive impairment
and AD, we addressed this research shortfall in a
large sample of non-demented community-dwelling
adults aged 44 to 48, and 64 to 68 years. Specif-
ically, we investigated if entorhinal cortex volumes
in these age-groups varied according to APOE geno-
type. Given the neuroanatomical proximity to the
entorhinal cortex and potential vulnerability to the
early pathological changes accompanying AD, we also
examined volumes for parahippocampal gyrus, tem-
poral pole, and inferior, middle, and superior temporal
cortices. Our key question was do APOE genotype vol-
ume differences in the entorhinal cortex and nearby
structures occur in middle age in a stepwise fashion
(i.e., ε2 > ε3 > ε4), and importantly, do any differences
become more marked or change in early old age?
METHODS
Participants
Participants were recruited from the Personality and
Total Health (PATH) Through Life study [16]. This is
a population-based study where the inclusion criteria
were (a) being listed on the electoral roll for Can-
berra and nearby Queanbeyan, Australia, and (b) being
within three narrow age range cohorts of 20–24, 40–44,
and 60–64 years at baseline in 1999, 2000, and 2001,
respectively. Participants were followed up every four
years. In contrast to clinical studies where there are
strict inclusion and exclusion criteria, the PATH study
adopts an epidemiological approach where participants
were recruited to be as representative of the catchment
area and age cohort as possible. Study procedures com-
plied with guidelines on human experimentation and
approval for the study was obtained from the Human
Research Ethics Committee of the Australian National
University.
This investigation concerns the second wave of data
for the middle aged and early old aged participants,
aged 44–48 and 64–68 years, respectively. The ini-
tial sample at Wave 2 consisted of 852 (431 + 421)
individuals who participated in the MRI substudy.
From the initial pool, participants who were suffering
from neurological disorders were removed as follows:
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epilepsy (n= 7), stroke (n= 26), head injury (n= 88).
People with data missing on APOE genotype (n= 45)
along with those with APOE genotype ε2/4 (see
below) were also removed (n= 26). All participants in
the older group were screened with the Mini-Mental
State Examination [17]. In order to eliminate possible
dementia cases, four persons were excluded as their
scores were below 24.
MRI acquisition
MRI acquisition parameters have been previously
described in detail elsewhere [18, 19]. Briefly, par-
ticipants were scanned on a 1.5T Philips Gyroscan
scanner (ACS-NT, Philips Medical Systems, Best, the
Netherlands) for T1-weighted 3D structural MRI in
coronal orientation and Fast Field Echo sequence,
TR = 8.93 ms, TE = 3.57 ms, flip angle of 8◦, matrix
size = 256 × 256, slices 160, and field of view (FOV)
256×256 mm, yielding contiguous slices with thick-
ness of 1.5 mm. In addition and due to factors outside
the investigators’ control, 268 middle aged subjects
were scanned on another scanner of the same type.
For those, the TR = 8.93 ms and TE = 3.57 ms values
were slightly adjusted to improve image quality, but
all other parameters were kept constant. In the mid-
dle aged group this variation was not associated with
significant differences in age, years of education, total
intracranial volume, gray matter volume, white matter
volume, or cerebrospinal fluid volume.
Image analysis
Volumetric segmentation was performed with the
Freesurfer image analysis suite, which is docu-
mented and freely available for download online
(http://surfer.nmr.mgh.harvard.edu/). This processing
includes motion correction, removal of non-brain tis-
sue using a hybrid watershed/surface deformation
procedure [20], automated Talairach transformation,
and segmentation of the subcortical white matter and
deep gray matter volumetric structures (including for
the present investigation, left and right volumes for
the entorhinal cortex, parahippocampal gyrus, tempo-
ral pole, and inferior, middle, and superior temporal
cortices), tessellation of the gray white matter bound-
ary, and topology correction [21–24]. The validity and
reliability of the Freesurfer package has been assessed
in a number of recent studies and was found to be very
good [18]. One scan was lost during acquisition from
the middle age-group and the scans of an additional 28
participants were excluded from the sample due to poor
scan quality, low signal-to-noise ratio, or movement
artifacts which did not allow for normal processing
with the standard Freesurfer pipeline. Each segmented
volume was inspected slice by slice and reprocessed
with additional parameters if errors were detected. Fol-
lowing these exclusions the final sample numbered 627
persons (314 and 313 in the middle aged and older
groups, respectively). The sample composition accord-
ing to age-group and APOE genotype is presented in
Table 1.
APOE genotyping
Genomic DNA was extracted from buccal swabs
using QIAGEN DNA Blood kits (#51162; QIAGEN,
Hilden, Germany). Two single-nucleotide polymor-
phisms (SNPs; rs429358 and rs7412) were genotyped
to identify APOE genotypes comprised of the APOE
ε2, ε3, and ε4 alleles using TaqMan assays (Applied
Biosystems [ABI], Foster City, CA) as described else-
where [25]. As ε2 is regarded as a protective factor
and ε4 a risk factor (ε3 is regarded as neutral), persons
with the ε2/4 genotype were removed from the sample
as they may weaken the contrast of primary inter-
est between ε2 and ε4. For this investigation, APOE
group composition was: ε2 = ε2/2 + ε2/3; ε3 = ε3/3;
ε4 = ε3/4 + ε4/4.
Episodic memory
Immediate and delayed recall was assessed as part
of a wider neuropsychological battery using the first
trial of the California Verbal Learning Test [26]. Par-
ticipants were required to remember 16 shopping list
items and to recall them immediately and again after a
delay of twenty minutes. As the two scores were highly
intercorrelated (0.87, p< 0.001), their mean is reported
here.
Health variables
Further to the exclusions detailed earlier, sev-
eral health variables were taken into account in
the statistical analyses: heart trouble, thyroid dis-
orders, diabetes, and hypertension. These variables
were coded 1 = complaint present, 2 = not present. We
adopted a conservative approach and coded missing
data 2. Hypertension was defined as either dias-
tolic blood pressure >90 or systolic blood pressure
>140.
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Table 1
Descriptive data for demographic, health, and neuroanatomical variables
ε2/2 + 2/3 ε3/3 ε3/4 + 4/4
M SD M SD M SD Recallb
Age-group 40s 43 1 43 1 43 1 −
60s 63 1 63 1 62 1 −
Gender (men/women)a 40s 18/27 − 76/107 − 35/51 − −
60s 23/18 − 99/94 − 43/36 − −
Years of education 40s 15 2 15 2 15 2 −
60s 13 3 14 3 14 2 −
APOEa 40s 45 − 183 − 86 − −
60s 41 − 193 − 79 − −
Heart troublea 40s 0 − 3 − 2 − −
60s 3 − 24 − 9 − −
Thyroid disordersa 40s 1 − 3 − 8 − −
60s 3 − 18 − 4 − −
Diabetesa 40s 0 − 5 − 3 − −
60s 4 − 20 − 9 − −
Hypertensiona 40s 9 − 42 − 17 − −
60s 18 − 97 − 34 − −
L entorhinal 40s 1736 299 1772 374 1726 285 0.14∗
60s 1788 281 1698 315 1661 314 0.08
R entorhinal 40s 1567 292 1618 332 1574 319 0.06
60s 1591 306 1604 302 1561 351 0.06
L parahippocampal 40s 1736 283 1763 279 1781 233 0.09
60s 1742 254 1692 242 1691 268 −0.06
R parahippocampal 40s 1565 211 1622 262 1602 241 −0.04
60s 1571 274 1525 232 1529 235 −0.07
L temporal pole 40s 2259 436 2233 406 2223 469 0.11
60s 2212 436 2234 401 2214 405 −0.02
R temporal pole 40s 2181 411 2236 401 2176 394 0.12∗
60s 2422 432 2339 442 2340 384 −0.03
L inferior temporal 40s 8991 1498 9210 1532 9319 1700 0.07
60s 8940 1870 8855 1502 8723 1737 −0.07
R inferior temporal 40s 8383 1490 8933 1499 8569 1738 0.04
60s 8460 1801 8051 1362 8027 1498 −0.03
L mid temporal 40s 10046 1911 10072 1481 10274 1601 0.13
60s 9595 1246 9517 1514 9415 1483 −0.07
R mid temporal 40s 11042 1478 10785 1516 11054 1612 0.10
60s 10723 1626 10548 1597 10499 1574 −0.12
L superior temporal 40s 11547 1858 11497 1533 11713 1647 0.07
60s 10855 1419 10742 1545 10927 1576 −0.10
R superior temporal 40s 10941 1612 10976 1404 11115 1323 −0.01
60s 10280 1235 10459 1518 10487 1354 −0.03
Notes. Brain volumes in mm3; L = Left; R = Right; a = refers to number of cases; b = regression beta weights having controlled for gender and
intracranial volume; ∗p< 0.05.
Statistics
A series of 2 × 2 × 3 Analysis of Covariance
(ANCOVA) were run where hemisphere (left, right)
served as a within-subjects factor, and age group
(middle age, older) and APOE group (2/2 + 2/3, 3/3,
3/4 + 4/4) as between-subject factors. We covaried
intracranial volume (to control for individual brain size
differences) and gender (to control for gender-related
differences in cortical volumes). Our main question
was whether cortical volumes varied according to
APOE group, and importantly, whether any significant
main effects were modified by age group.
RESULTS
Descriptive data for demographic, health, and brain
volume variables according to APOE genotype and
age are presented in Table 1. Given the association
between the temporal lobes and episodic memory, for
descriptive purposes, coefficients between the recall
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measure and brain volumes are also included in that
table. Summary statistics and effect sizes for the
ANCOVAs assessing cortical volumes according to
hemisphere, age group, and APOE genotype are pre-
sented in Table 2.
There were several notable findings. First, with one
exception, all of the main effects and higher-order
interactions involvingAPOEwere nonsignificant. Sec-
ond, for entorhinal cortex volume, none of the other
main effects or interactions were significant. Third, all
of remaining main effects for age were significant, with
the majority indicating middle aged persons recorded
higher volumes than older participants. The excep-
tion was temporal pole, where opposite was the case.
The main effect for hemisphere was also significant
for temporal pole with right volumes greater than left
volumes. However, this largely stemmed from older
persons, as a significant Age × Hemisphere interac-
tion indicated right hemisphere volumes to be larger
in this group. That interaction was also significant for
the middle temporal volume. Here though, the trend
was toward greater right hemisphere volumes in both
middle aged and older participants. The effect size
for this interaction, however, was small. Finally, there
was a significant Age ×APOE× Hemisphere interac-
tion for inferior temporal lobe volume. ANCOVAs to
identify the source of this interaction found the Age
group ×APOE interaction for the left hemisphere was
nonsignificant. For the right hemisphere however, that
interaction was significant (p< 0.05). Although there
was a trend suggesting a decline in volumes in the older
group that followed a ε2 > ε3 > ε4 pattern, the source of
the interaction stemmed from younger ε3 carriers who
had greater volumes. This was confirmed by a series of
Bonferroni adjusted T-tests where only the age group
comparison for ε3 carriers was significant (p< 0.05).
Again though, it should be noted that the effects size
relating to this interaction was small.
We repeated the ANCOVAs with handedness and
years of education as additional covariates, but this
did not change the pattern of the original findings.
We also reran the ANCOVAs using the more con-
servative MMSE cutoff of ≤26 in the older group
(13 persons were excluded). With two exceptions, the
overall pattern of findings did not change for these
analyses using the more homogeneous group. The
exceptions were for inferior temporal volume where
the Age ×APOE× Hemisphere interaction became
marginally nonsignificant (p= 0.052). Similarly, the
Age × Hemisphere interaction for middle temporal
volume became marginally nonsignificant (p= 0.051).
As an example of the overlap between APOE groups,
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Fig. 1. Left entorhinal cortex volume as a function of age andAPOE.
Fig. 1 provides a boxplot of left entorhinal cortex vol-
umes in this more homogeneous group according to
age and APOE.
Finally, we repeated the analyses controlling for
the health variables heart trouble, thyroid disorders,
diabetes, and hypertension. With one exception, this
made no difference to our original findings. The excep-
tion was heart trouble where the significant main
effect for hemisphere in respect to temporal pole
became nonsignificant. Also, as some of the partici-
pants were scanned on a different scanner, we repeated
the analyses covarying type of scanner. Here, the find-
ings were as in the original analyses except for the
Age × Hemisphere interaction for middle temporal
pole, which became nonsignificant.
DISCUSSION
This is the largest population-based study of the
entorhinal cortex and APOE genotype in cognitively
intact adults in midlife (44 to 48 years) and early old
age (64 to 68 years). Due to their vulnerability to the
neuropathological changes associated with AD, other
structures in the medial temporal lobe were also exam-
ined including the parahippocampal gyrus, temporal
pole, and inferior, middle, and superior temporal cor-
tices. Additionally, the sample was sufficiently large
to systematically contrast the relative effects of the ε2,
ε3, and ε4 alleles. Several notable findings emerged
from the study. First, there was no evidence that APOE
genotype influenced brain volumes in a stepwise fash-
ion (i.e., ε2 > ε3 > ε4) in middle age or early old age.
Second, there were several significant age effects, the
majority indicating that older participants recorded
smaller volumes. Additionally, using a more conser-
vative MMSE cutoff of ≤26 made little difference to
the original pattern of findings. Finally, taking several
health variables, handedness and years of education
into account in the statistical analyses did not substan-
tially alter our main findings.
The entorhinal cortex is of particular interest in the
present context as both neuroimaging [8, 9], and post-
mortem studies [10] have shown it is one of the main
brain structures to exhibit the early neuropathologi-
cal changes associated with AD. Although there have
been previous studies showing that APOE genotype is
associated with entorhinal cortex size in cognitively
intact older adults [12–15], the findings are mixed and
none have systematically assessed entorhinal cortex
volume in midlife and young old age while contrasting
the ε2, ε3, and ε4 alleles. Given evidence that posses-
sion of the ε4 allele is a risk factor for AD [5] while
the ε2 allele offers protection [6], the present finds
are of some importance. Specifically, although there is
work suggesting a ε2 > ε3 > ε4 pattern in relation to the
entorhinal cortex thickness in early life [1], the present
findings suggest that in middle age and into early old
age, this trend is absent.
There are several possible explanations for this find-
ing. The first is that the absence of this trend reflects
a Type II error and therefore, should be treated with
caution. This seems unlikely however, as the analyses
involved 627 persons and the design offered sufficient
statistical power to detect small to medium effect sizes
at the five percent alpha level. The second possibility
is that the APOE associations with brain morphology
are related to neurodevelopment in early life and neu-
rodegeneration in later life and the present sample aged
44 to 48, and 64 to 68, years fell between those two
extremes. It is of note that studies finding an associa-
tion between the ε4 allele and entorhinal cortex metrics
have either involved participants older than those in
the present study [15] or involve persons with a fam-
ily history of AD who are therefore at greater risk of
the disease [12]. Although associations between the
ε4 allele and neuroanatomical volumes in other parts
of the brain have been detected in middle age persons
[27, 28], it is possible that APOE-related effects on
the entorhinal cortex and nearby structures occur either
with older age or in persons with a greater vulnerability
to AD.
A related explanation stems from work suggest-
ing the subclinical phase of the disease extends years
and perhaps decades in advance of eventual diagno-
sis. For example, cognitive deficits have been detected
up to ten years in advance of diagnosis [29], and
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histopathological work suggests that the neuropathol-
ogy associated with AD is present decades before
emergence of the disease [30]. Given the long pre-
clinical phase of AD, and that possession of the ε4
allele increases the risk of the disease, it is possible
that where associations with the entorhinal cortex are
found, it is in persons who eventually develop AD.
As the PATH Through Life project is ongoing, we
do not currently have data on AD status as it will be
collected over the coming years. However, the lack
of APOE-entorhinal cortex effects may be due to the
largely healthy, cognitively normal population-based
sample and the possibility that relatively few individ-
uals will eventually suffer AD. This possibility will be
addressed in future research.
Although not the main focus of the present study,
there were also some significant hemisphere effects
indicating left temporal pole and middle temporal vol-
umes to be smaller. Work suggesting greater left than
right atrophy in mild cognitive impairment and AD
[19, 31] may explain this finding, although there is
also conflicting evidence [32]. However, the lack of
information for the present sample on future dementia
status already noted makes this explanation uncertain.
Additionally, several effects for hemisphere became
nonsignificant in repeat analyses with a more stringent
MMSE cutoff and when heart trouble was taken into
account. Together, given the large sample and that most
of the significant statistics involved small effect sizes,
the findings in relation to hemisphere should be treated
with caution.
Although the study possesses several strengths,
there are also some limitations that we should acknowl-
edge. First, in order to robustly test theAPOE genotype
effect, we would have preferred to contrast ε2 and ε4
homozygotes. Although to date, the present study is
the largest in non-demented adults to directly contrast
the three alleles, there were insufficient numbers pos-
sessing the ε2/2 and ε4/4 genotypes to achieve this.
However, as with work elsewhere [1], we believe our
strategy of removing ε2/4 s, and combining ε2/2 with
ε2/3 s, and ε3/4 s with ε4/4 s, and evaluating relative
to ε3/3 s provided a sufficiently robust test of the main
hypothesis. Additionally, although not a limitation, the
present study focused on non-demented persons with
a maximum age of 68 years. As noted earlier, it is
possible that participants were too young to detect
the hypothesized APOE-related effects. Finally, for
reasons beyond our control, some middle aged par-
ticipants were scanned on a different scanner to the
rest of that group. However, both scanners were 1.5T
Philips scanners with the same acquisition parameters,
and five controls were scanned on both scanners and
no significant volumetric differences were observed.
Moreover, as repeating the analyses with scanner type
entered as a covariate had little influence on the origi-
nal findings, it does not appear that scanner differences
had a major bearing on the main study outcomes.
To conclude, our findings suggests that APOE geno-
type is not associated with entorhinal cortex volume, or
those of other structures in the medial temporal lobe,
in cognitively normal community-dwelling adults in
midlife and early old age up to 68 years. It is possi-
ble that the association between APOE genotype and
entorhinal cortex metrics is a feature of neurodevelop-
ment in early life and neurodegeneration in late life,
and that the ages of the present sample fell between
those two extremes. Moreover, associations where they
are found in older persons may be related to the sub-
clinical phase of AD that extends years in advance of
eventual diagnosis. As the entorhinal cortex is one of
the first brain structures to exhibit the pathology asso-
ciated with the disease and may give an early indication
of vulnerability to eventual AD, it is important that fur-
ther work explores the influence of risk factors such as
APOE genotype on this brain structure in midlife and
early old age.
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